Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Peritoneal cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Y-mAbs Therapeutics
- 18 Jun 2018 Planned number of patients changed from 45 to 51.
- 03 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 03 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.